关键词：他汀类药物；HMG-CoA；还原酶抑制；药物作用；胆固醇合成剂；心血管；有益效果
摘 要：Statins (or HMG-CoA reductase inhibitors) are structural analogs of the HMG-CoA enzyme. It shows its pharmaceutical action by inhibiting HMG-CoA reductase, the key enzyme involved in cholesterol synthesis. Statins have been known to have a beneficial effect on cardiovascular morbidity and mortality. Its significant anti-inflammatory and plaque-stabilizing effects have added to its larger usage. It also helps decrease oxidative stress and vascular inflammation with increased atherosclerotic lesions. Some of the currently available statins are atorvastatin, lovastatin, rosuvastatin, and simvastatin.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Product Profile

05.1 Crestor

05.2 Caduet

05.3 Lescol

05.4 Lipitor

05.5 Liptruzet

05.6 Mevacor

05.7 Vytorin

05.8 Zocor

06. Introduction

07. Statin: An Overview

07.1 Statin Pharmacophore

07.2 Mechanism of Action

07.2.1 Different Class of Lipoproteins

07.3 Clinical Application

07.4 Treatment Guidelines

08. Pipeline Portfolio

08.1 HL040

08.2 Livasartan

08.3 BCWP-C001

08.4 CJ-30056

09. Market Landscape

09.1 Market Overview

09.1.1 Market Size and Forecast

09.2 Statin Market in US 2014-2019

09.2.1 Market Size and Forecast

09.3 Five Forces Analysis

10. Market Segmentation by Product Category

10.1 Type 1 Statins

10.1.1 Lovastatin

10.1.2 Pravastatin

10.1.3 Simvastatin

10.2 Type 2 Statins

10.2.1 Atorvastatin

10.2.2 Fluvastatin

10.2.3 Rosuvastatin

11. Geographical Segmentation

11.1 Global Statin Market by Geographical

Segmentation 2014-2019

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2014

19.2.1 AstraZeneca

19.2.2 Merck

19.2.3 Novartis

19.2.4 Pfizer

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 AstraZeneca

20.1.1 Key Facts

20.1.2 Business Overview

20.1.3 Business Segmentation by Revenue 2013

20.1.4 Business Segmentation by Revenue 2011-2013

20.1.5 Sales by Geography

20.1.6 Business Strategy

20.1.7 Key Developments

20.1.8 SWOT Analysis

20.2 Merck

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation by Revenue 2013

20.2.4 Business Segmentation by Revenue 2012 and 2013

20.2.5 Sales by Geography

20.2.6 Business Strategy

20.2.7 Key Developments

20.2.8 SWOT Analysis

20.3 Novartis

20.3.1 Key Facts

20.3.2 Business Description

20.3.3 Business Segmentation

20.3.4 Revenue by Business Segmentation

20.3.5 Revenue Comparison 2012 and 2013

20.3.6 Sales by Geography

20.3.7 Business Strategy

20.3.8 Key Developments

20.3.9 SWOT Analysis

20.4 Pfizer

20.4.1 Key facts

20.4.2 Business Overview

20.4.3 Business Segmentation by Revenue 2014

20.4.4 Business Segmentation by Revenue 2013 and 2014

20.4.5 Geographical Segmentation by Revenue 2014

20.4.6 Business Strategy

20.4.7 Key Developments

20.4.8 SWOT Analysis

21. Other Reports in this Series